Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children

Pediatric Nephrology

Volumn 22, Issue 2, 2007, Pages 282-287

  Waterhouse, Kim M ^a   Auron, Ari ^a   Srivastava, Tarak ^a   Haney, Connie ^a   Alon, Uri S ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Bisphosphonates; Bone density; Bone turnover markers; Fractures; Metabolic bone disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBUPROFEN; PAMIDRONIC ACID; PARACETAMOL; SODIUM CHLORIDE; VITAMIN D; ZOLEDRONIC ACID;

ADOLESCENT; ALBERS SCHOENBERG DISEASE; ARTICLE; BONE DENSITY; BONE PAIN; BONE RADIOGRAPHY; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LUMBAR SPINE; MALE; METABOLIC BONE DISEASE; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SIDE EFFECT; TOOTH PAIN;

ADOLESCENT; BONE DENSITY; BONE DISEASES, METABOLIC; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OSTEOGENESIS; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TIME;

EID: 33845719009     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0306-0     Document Type: Article

References (44)

1. Srivastava T, Alon US (2003) The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162:735-751
2. Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417-423
3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
4. Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C (2002) Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 15(Suppl 3):929-937
5. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F (2000) Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum 43:1960-1966
6. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet 363:1427-1431
7. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977-986
8. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adams S (2005) Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. J Bone Miner Res 20:758-763
9. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573-578
10. Acott PD, Wong JA, Lang BA, Crocker JF (2005) Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 20:368-373
11. Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175-195
12. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575
13. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463
14. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, Walker PD (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634-641
15. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289
16. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761
17. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell C (2004) Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 145:701-704
18. Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI (1999) Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia. J Pediatr 135:182-188
19. Leib ES, Lewiecki EM, Binkley N, Hamdy RC (2004) International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. South Med J 97:107-110
20. Zoledronate (Zometa) (2001) Med Lett Drugs Ther 43:110-111
21. Van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S (1994) Structural requirements for bisphosphonates actions in vitro. J Bone Miner Res 9:1875-1882
22. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
23. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786-791
24. Vyskocil V, Pikner R, Kutilek S (2005) Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 72:416-423
25. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT (2004) Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 145:701-704
26. Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CC, van Zuylen L (2005) Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 20:1543-1547
27. Lasseter KC, Porras AG, Denker A, Santhanagopal A, Daifotis A (2005) Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Invest 25:107-114
28. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S (1994) Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837
29. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE (1995) Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80:3465-3468
30. Langman CB, Arwady AL, Price H (2005) Bone after cessation of alendronate use in children with fracturing osteoporosis [abstract]. J Bone Miner Res 20:S245
31. Khosla S, Melton LJ, Dekutoski MB, Achenbach SJ, Oberg AL, Riggs BL (2003) Incidence of childhood distal forearm fractures over 30 years. JAMA 290:1479-1485
32. Cooper C, Dennison E, Leufkens HGM, Bishop N, Van Staa TP (2004) Epidemiology of childhood fractures in Britain: A study using the general practice research database. J Bone Miner Res 19:1976-1981
33. Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111:1030-1036
34. Brumsen C, Hamdy N, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton:sTudies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283
35. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 44:813-818
36. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534
37. American Dental Association (2006) Dental management of patients receiving oral bisphosphonate therapy - Expert panel recommendations. June. http://www.ada.org/prof/resources/topics/ topics_osteonecrosis_recommendations.pdf
38. Plotkin H, Bruzoni M, Coughlin S, Lerner G, Allbery S, Schroeder B, Heldt K, Grovas L, Kreikemeier R (2005) Low doses of pamidronate for the treatment of osteoporosis in children with cerebral palsy [abstract]. J Bone Miner Res 20:S280
39. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
40. Federico G, Baroncelli GI, Vanacore T, Fiore L, Saggese G (2003) Pubertal changes in biochemical markers of growth. Horm Res 60:46-51
41. Van der Sluis IM, Hop WC, van Leeuwen JP, Pols HA, de Muinck Keizer-Schrama SM (2002) A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults. Horm Res 57:170-179
42. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, Abbiati G, Chiumello G (1998) Urinary markers of bone turnover in healthy children and adolescents: Age-related changes and effect of puberty. Calcif Tissue Int 63:369-374
43. Tommasi M, Bacciottini L, Benucchi A, Passeri A, Saracini D, D'Agata A, Cappelli G (1996) Serum biochemical markers of bone turnover in healthy infants and children. Int J Biol Markers 11:159-164
44. Khosla S, Kleerekoper M (2003) Biochemical markers of bone turnover. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society for Bone and Mineral Research, Washington, D.C., pp. 166-172